Nitayaphan et al., "Vaccination with ALVAC and AIDSVAX
to prevent HIV-1 infection in Thailand," The New England Journal of Medicine, vol.
Concurrently, the eligible participants in HVTN 114 will receive either another MVA62B boost, a combined boost of MVA62B and AIDSVAX
B/E, or AIDSVAX
(8.) Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al., Vaccination with ALVAC and AIDSVAX
to prevent HIV-1 infection in Thailand.
This in turn led to a new trial (RV 144 in Thailand) to test a canarypox vector vaccine (ALVAC-HIV) boosted with a recombinant glycoprotein vaccine (AIDSVAX
Results from a recent vaccine trial in Thailand demonstrated preliminary efficacy of a combination ALVAC-HIV and AIDSVAX
B/E vaccine regimen among a community-based sample consisting mostly of relatively low-risk heterosexuals (Rerks-Ngarm et al.
It was designed to prime HIV-1-specific cell-mediated immunity and was then followed by two injections of a recombinant glycoprotein gp120 subunit vaccine containing concentrations of subtype B and E antigens designed to boost HIV-1 cell-mediated immunity and stimulate neutralising HIV-1 antibodies (AIDSVAX
The booster dose, AIDSVAX
B/E, is a glycoprotein 120 vaccine.
The unexpected result puzzled researchers, who say they cannot figure out why the drug - a combination of canary pox vaccine and the failed HIV vaccine Aidsvax
- is working.
The vaccines used during the trials were ALVAC, from Sanofi Pasteur, the vaccine division of French drugmaker Sanofi-Aventis and AIDSVAX
, developed by VaxGen Inc.
They are ALVAC, from Sanofi Pasteur, the vaccine division of French drugmaker Sanofi-Aventis; and AIDSVAX
, originally developed by VaxGen Inc.
The vaccine is a combination of Sanofi-Aventis ALVAC canary pox vaccine and HIV vaccine AIDSVAX
, made by VaxGen, Reuters reported.